Amarin Corporation plc (AMRN)
After hours:
- GlobeNewswire
Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs
DUBLIN, Ireland and BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that research on the potential population health impact and cost-effectiveness of VASCEPA® (icosapent ethyl), presented in two poster presentations at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022, showcased significant potential to reduce major cardiovascular (CV) events and associated costs. The
- Zacks
New Strong Sell Stocks for May 13th
DDD, AMRN, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2022.
- GlobeNewswire
Amarin to Present at Two Upcoming Investor Conferences
DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, will present at two upcoming investor conferences: H.C. Wainwright Global Investment Conference (May 23-26, 2022; Miami, Florida) Date/Time: May 25, 2022, 12:00 p.m. ET/5:00 p.m. GMT+1Webcast: https://journey.ct.events/view/7aff40b1-3f90-47dd-a827-a30d854fea27 Jefferies Healthcare Conference (June 8-10, 20
